Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.38 |
| ▸ | TTR | P02766 | 4/20 | 0.36 |
| ▸ | EYA3 | Q99504 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181586 | 0.78 | MAPK1 (0.45) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL24592732 | 0.75 | CYP2C19 (0.35) | CYP2C19 | |
| SCHEMBL18629847 | 0.73 | SLC22A12 (0.43) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL18629885 | 0.73 | SLC22A12 (0.38) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL20181390 | 0.73 | SLC22A12 (0.39) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL18629839 | 0.72 | MAPK1 (0.46) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL18629835 | 0.72 | RAB9A (0.44) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL20181579 | 0.71 | SLC22A12 (0.37) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL21176882 | 0.71 | SLC22A12 (0.37) | SLC22A12TTREYA3PTPN1CYP2C9 | |
| SCHEMBL18629767 | 0.71 | USP7 (0.38) | SLC22A12TTREYA3PTPN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | claimed |
| CN-108084186-B | URAT1 inhibitor and application thereof | 江苏新元素医药科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | claimed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | claimed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | claimed |
| US-RE50083-E1 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2024-08-20 | — | — | US | disclosed |
| EP-3543240-B1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| CN-108084186-B | URAT1 inhibitor and application thereof | 江苏新元素医药科技有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-10875865-B2 | URAT1 inhibitor and use thereof | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543240-A1 | URAT1 INHIBITOR AND USE THEREOF | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018090921-A1 | URAT1 INHIBITOR AND USE THEREOF | 江苏新元素医药科技有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062763-A1 | URAT1 INHIBITOR AND USE THEREOF | SLC14A1, SLC10A6, SLC10A1 | SLC22A12 39/4885TTR 2356/4885EYA3 2921/4885 |
| US-10875865-B2 | URAT1 inhibitor and use thereof | SLC14A1, SLC10A6, SLC10A1 | SLC22A12 39/4885TTR 2356/4885EYA3 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.